Bio-Thera Out-Licenses Ex-China Rights for Avastin Biosimilar to Sandoz
publication date: Sep 8, 2021
Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz. Sandoz will also have rights in most other countries not already assigned. In 2020, Bio-Thera filed BLAs for BAT1706 in these countries, plus China. Financial details of the agreement were not disclosed but, last year, Bio-Thera out-licensed China rights for the candidate to BeiGene in a $165 million deal. It also out-licensed emerging market rights to India's Cipla. Bio-Thera is headquartered in Guangzhou. More details....
Stock Symbols: (SHA: 688177)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.